To further address whether other MAPKs, including JNK and/or ERK signaling, are implicated in these processes, we also analyzed the regulatory state of these kinases in response to treatment with the three naphthalimide-NHC derivatives, as, for instance, JNK activation and/or ERK inhibition, which has been previously reported in the anti-cancer efficacy of several other organometallic drugs [27,34,35]. This evidence concerns the gene MAPK8 and cancer.